首页/数据集/Supplementary Material - Ritlecitinib for Severe Alopecia Areata in Children Under 12 Years: A Retrospective Review of 18 Cases

Supplementary Material - Ritlecitinib for Severe Alopecia Areata in Children Under 12 Years: A Retrospective Review of 18 Cases

Mendeley Data2026-04-09 收录

儿科斑秃治疗

JAK抑制剂临床试验

数据链接：

https://data.mendeley.com/datasets/whsv74wzr9/1 数据链接链接失效反馈

官方服务：

资源简介：

Supplementary Material - Ritlecitinib for Severe Alopecia Areata in Children Under 12 Years: A Retrospective Review of 18 Cases

应用场景：

特应性皮炎治疗

JAK抑制剂临床试验

This phase 1b, single-center, double-blind study evaluated safety, efficacy, and effect on molecular profiles of a topical Janus kinase/spleen tyrosine kinase (JAK/Syk) inhibitor, cerdulatinib gel 0.3

NIAID Data Ecosystem150

Supplementary Material for: Darier’s Disease Successfully Treated with Tofacitinib: A Case Report

罕见皮肤病

JAK抑制剂临床试验

Darier’s disease (DD) is a rare autosomal dominant genodermatosis characterized by keratotic papules, predominantly affecting seborrheic areas. We report a 42-year-old woman who developed pruritic bro

NIAID Data Ecosystem80

The Role of Interferon-? in Autoimmune Polyendocrine Syndrome Type 1

自身免疫疾病机制

JAK抑制剂临床试验

Background: Autoimmune polyendocrine syndrome type 1 (APS-1) is a life-threatening, autosomal recessive syndrome caused by autoimmune regulator (AIRE) deficiency. In APS-1, self-reactive T cells escap

NIAID Data Ecosystem20

Table_1_COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm.docx

细胞因子治疗

JAK抑制剂临床试验

Since SARS-CoV-2 outbreak in December 2019, world health-system has been severely impacted with increased hospitalization, Intensive-Care-Unit (ICU) access and high mortality rates, mostly due to seve

NIAID Data Ecosystem90

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis

强直性脊柱炎治疗

JAK抑制剂临床试验

The purpose of this study is to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroid

DataCite Commons2025-04-01 更新30

Supplementary Material - Ritlecitinib for Severe Alopecia Areata in Children Under 12 Years: A Retrospective Review of 18 Cases

资源简介：

相关数据集